Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
5 Analysts Have This to Say About NeuroPace
Over the past 3 months, 5 analysts have published their opinion on NeuroPace (NASDAQ:NPCE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Recap: NeuroPace Q1 Earnings
NeuroPace (NASDAQ:NPCE) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
NeuroPace missed estimated earnings by 6.82%, reporting an EPS of $-0.47 versus an estimate of $-0.44.
NeuroPace Announces First Patient Treated In Pivotal Study Evaluating The RNS System In Adolescents
NeuroPace, Inc. a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced that the first patient was treated in the RESPONSE clinical trial, which will evaluate
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 211 companies set new 52-week lows.
Expert Ratings For NeuroPace
Analysts have provided the following ratings for NeuroPace (NASDAQ:NPCE) within the last quarter:
Wells Fargo Maintains Equal-Weight on NeuroPace, Lowers Price Target to $9
Wells Fargo analyst Lawrence Biegelsen maintains NeuroPace (NASDAQ:NPCE) with a Equal-Weight and lowers the price target from $11 to $9.
SVB Leerink Maintains Outperform on NeuroPace, Lowers Price Target to $12
SVB Leerink analyst Danielle Antalffy maintains NeuroPace (NASDAQ:NPCE) with a Outperform and lowers the price target from $15 to $12.